PE20221727A1 - Dosificacion qw de compuestos peptidicos agonistas del receptor de gip y sus usos - Google Patents

Dosificacion qw de compuestos peptidicos agonistas del receptor de gip y sus usos

Info

Publication number
PE20221727A1
PE20221727A1 PE2022002091A PE2022002091A PE20221727A1 PE 20221727 A1 PE20221727 A1 PE 20221727A1 PE 2022002091 A PE2022002091 A PE 2022002091A PE 2022002091 A PE2022002091 A PE 2022002091A PE 20221727 A1 PE20221727 A1 PE 20221727A1
Authority
PE
Peru
Prior art keywords
receptor agonist
agonist peptide
gip receptor
peptide compounds
dosage
Prior art date
Application number
PE2022002091A
Other languages
English (en)
Inventor
Antoine Charles Olivier Henninot
Derek Cecil Cole
Nicholas Scorah
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PE20221727A1 publication Critical patent/PE20221727A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgacion proporciona compuestos peptidicos agonistas del receptor de GIP adecuados para dosificacion una vez a la semana (QW), en los que dichos compuestos peptidicos tienen una accion activadora sobre los receptores de GIP, y el uso del peptido agonista del receptor de GIP como medicamento para el tratamiento y/o la prevencion de la emesis o un sintoma o una afeccion asociados con la emesis. Especificamente, se proporciona un peptido agonista del receptor de GIP que contiene una secuencia representada por cualquiera de las formulas (I)-(V) o una sal de este y un medicamento que lo comprende.
PE2022002091A 2020-03-25 2021-03-25 Dosificacion qw de compuestos peptidicos agonistas del receptor de gip y sus usos PE20221727A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062994721P 2020-03-25 2020-03-25
PCT/JP2021/014422 WO2021193983A2 (en) 2020-03-25 2021-03-25 Qw dosing of gip receptor agonist peptide compounds and uses thereof

Publications (1)

Publication Number Publication Date
PE20221727A1 true PE20221727A1 (es) 2022-11-04

Family

ID=75674909

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002091A PE20221727A1 (es) 2020-03-25 2021-03-25 Dosificacion qw de compuestos peptidicos agonistas del receptor de gip y sus usos

Country Status (17)

Country Link
US (1) US20230143604A1 (es)
EP (1) EP4126920A2 (es)
JP (1) JP2023524603A (es)
KR (1) KR20220157409A (es)
CN (1) CN115916812A (es)
AR (1) AR121649A1 (es)
AU (1) AU2021243671A1 (es)
BR (1) BR112022019110A2 (es)
CA (1) CA3172241A1 (es)
CL (1) CL2022002597A1 (es)
CO (1) CO2022014960A2 (es)
EC (1) ECSP22074715A (es)
IL (1) IL296219A (es)
MX (1) MX2022011729A (es)
PE (1) PE20221727A1 (es)
TW (1) TW202202517A (es)
WO (1) WO2021193983A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
NZ540381A (en) 2002-11-01 2007-11-30 Takeda Pharmaceutical 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy
WO2004041266A1 (ja) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited 受容体機能調節剤
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
CA2550012A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same and use
BRPI0418148A (pt) 2003-12-25 2007-04-17 Takeda Pharmaceutical composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
WO2005095338A1 (ja) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
CA2617969A1 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
ME00535B (me) 2006-06-27 2011-10-10 Takeda Pharmaceuticals Co Fuzionisana ciklična jedinjenja
CA2660835A1 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable propperties
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
NZ576570A (en) 2006-10-19 2010-11-26 Takeda Pharmaceutical 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
WO2008099794A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
KR20130133103A (ko) * 2008-08-07 2013-12-05 입센 파마 에스.에이.에스 Ｎ-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(ｇｉｐ)의 유사체
JOP20180028A1 (ar) * 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد

Also Published As

Publication number Publication date
WO2021193983A8 (en) 2023-05-25
EP4126920A2 (en) 2023-02-08
ECSP22074715A (es) 2022-10-31
CN115916812A (zh) 2023-04-04
JP2023524603A (ja) 2023-06-12
AU2021243671A1 (en) 2022-10-13
MX2022011729A (es) 2022-10-13
IL296219A (en) 2022-11-01
WO2021193983A3 (en) 2021-11-04
BR112022019110A2 (pt) 2023-01-17
WO2021193983A2 (en) 2021-09-30
AR121649A1 (es) 2022-06-22
TW202202517A (zh) 2022-01-16
CO2022014960A2 (es) 2022-11-08
CA3172241A1 (en) 2021-09-30
KR20220157409A (ko) 2022-11-29
CL2022002597A1 (es) 2023-06-02
US20230143604A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
CO2019012271A2 (es) Péptido activador de receptor de gip
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
ECSP15044389A (es) Compuesto peptídico
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
CL2022002597A1 (es) Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos
CL2017001024A1 (es) Formulación de buprenorfina inyectable
DOP2019000070A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CO2022009510A2 (es) Compuestos activos frente a receptores nucleares
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CO2022014959A2 (es) Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos
CO2018011353A2 (es) Dispositivo de inyección mecánico para descargar múltiples formulaciones líquidas, incluso vacunas
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
AR101806A1 (es) Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominio
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
DOP2019000071A (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
CO2020002967A2 (es) Desinfectante novedoso para criaderos
AR102248A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes
CL2018003707A1 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo.
AR121581A1 (es) Formulaciones líquidas de análogos de glucagón
CO2021018031A2 (es) Una composición farmacéutica para la diabetes mellitus
CL2023000977A1 (es) Compuestos de tetrahidrobenzofurodiazepinona y usos farmacéuticos de los mismos